The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Pyrimethamine-Clindamycin vs. Pyrimethamine-Sulfadiazine as Acute and Long-Term Therapy for Toxoplasmic Encephalitis in Patients with AIDS
Open accessAbstract
This European multicenter study compares the efficacy and tolerance of the combination of pyrimethamine-clindamycin (Pyr-Cm) with the standard therapy pyrimethamine-sulfadiazine (Pyr-Sdz) for the treatment of toxoplasmic encephalitis (TE) in patients with AIDS. Two hundred ninety-nine human immunodeficiency virus-infected patients with TE were randomly assigned to receive 50 mg of pyrimethamine daily combined with either 2,400 mg of clindamycin or 4 g of sulfadiazine for 6 weeks followed by maintenance therapy with 25 mg of pyrimethamine daily with either 1,200 mg of clindamycin or 2 g of sulfadiazine. An intent-to-treat analysis showed that Pyr-Cm was less effective than Pyr-Sdz; the overall risk of progression of TE was 1.84 times higher for patients receiving Pyr-Cm therapy. There was no statistically significant difference in efficacy during acute therapy, although the rate of crossover motivated by a lack of response was higher among Pyr-Cm recipients. The difference in efficacy was evidenced during the maintenance phase of treatment; the relapse rate was twice as high among patients in the Pyr-Cm group (P = .02). The rate of side effects due to both regimens was similar, although the toxic effects of Pyr-Cm led to fewer discontinuations of therapy than did those of Pyr-Sdz (11% vs. 30%, respectively; P = .001). Pyr-Sdz appears to be the most effective treatment of TE. Pyr-Cm is a valuable alternative but is less effective for long-term prevention of relapses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxoplasmic Encephalitis in AIDS
Luft, B. J., & Remington, J. S. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/15.2.211 · Cited by 1,287
Toxoplasmic Encephalitis in Patients With Acquired Immune Deficiency Syndrome
Luft, B. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03350070031018 · Cited by 714
Toxoplasmosis of the Central Nervous System in the Acquired Immunodeficiency Syndrome
Porter, S. B., & Sande, M. A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212033272306 · Cited by 670
Toxoplasmic Encephalitis in Patients with the Acquired Immunodeficiency Syndrome
Luft, B. J., Hafner, R., Korzun, A. H., Leport, C., Antoniskis, D., Bosler, E. M., Bourland, D. D., Uttamchandani, R., Fuhrer, J., Jacobson, J., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291403 · Cited by 405
Dannemann, B., McCutchan, J. A., Israelski, D., Antoniskis, D., Leport, C., Luft, B., Nussbaum, J., Clumeck, N., Morlat, P., Chiu, J., et al. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-1-33 · Cited by 360
Self-citationTreatment of Toxoplasmic Encephalitis With Intravenous Clindamycin
Dannemann, B. R. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.148.11.2477 · Cited by 89
Cited by
Masur, P. B. H., Kaplan, J. E., & Holmes, K. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00002 · Cited by 567
Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice
Dunay, I. R., Gajurel, K., Dhakal, R., Liesenfeld, O., & Montoya, J. G. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00057-17 · Cited by 553
Gemmell, C. G., Edwards, D. I., Fraise, A. P., Gould, F. K., Ridgway, G. L., & Warren, R. E. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl017 · Cited by 439
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 360
Drugs in development for toxoplasmosis: advances, challenges, and current status
Alday, H., & Doggett, J. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s60973 · Cited by 321
Metadata
- Authors
- Katlama, C., De Wit, S., O'Doherty, E., Van Glabeke, M., Clumeck, N., & European Network for Treatment of AIDS (ENTA) Toxoplasmosis Study Group
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-02-01
- Volume
- 22
- Issue
- 2
- Pages
- 268-275
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2124445355
- Cited by
- 253
- References
- 6
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pyrimethamine-Clindamycin vs. Pyrimethamine-Sulfadiazine as Acute and Long-Term Therapy for Toxoplasmic Encephalitis in Patients with AIDS. https://app.cochat.ai/papers/10.1093/clinids/22.2.268
- The paper
- Katlama, C., De Wit, S., O'Doherty, E., Van Glabeke, M., Clumeck, N., & European Network for Treatment of AIDS (ENTA) Toxoplasmosis Study Group. (1996). Pyrimethamine-Clindamycin vs. Pyrimethamine-Sulfadiazine as Acute and Long-Term Therapy for Toxoplasmic Encephalitis in Patients with AIDS. Clinical Infectious Diseases. https://doi.org/10.1093/clinids/22.2.268
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.